Pharmafile Logo
Pharmafocus logo
Advanced Search

Cancer

Showing 15 posts of 1067 posts found.

fda2outsideweb

FDA approves first oral TRK inhibitor with Loxo Oncology’s Vitrakvi

November 27, 2018
Manufacturing and Production, Sales and Marketing Cancer, FDA, Loxo Oncology, Vitrakvi, oncology, pharma

The FDA has announced the approval of the United States’ first-ever oral tyrosine kinase (TRK) inhibitor, Loxo Oncology’s Vitrakvi (larotrectinib), …

News

Immuno Biotech owner promoting unlicensed ‘cure’ for cancer, autism and HIV to be sentenced next week

November 23, 2018
Medical Communications Cancer, David Noakes, GcMAF, HIV, UKIP, autism

The owner of Guernsey-based biotech Immuno Biotech Ltd, David Noakes, will be sentenced this week after admitting to a number …

News

Cancer Drugs Fund to offer MSD’s Keytruda for lung cancer

November 22, 2018
Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NICE, UK, keytruda, pharma

MSD’s Keytruda (pembrolizumab) will now be made available via the Cancer Drugs Fund for patients in England, as NICE announces …

News
shutterstock_159488225

Merck KGaA and Pfizer’s Bavencio falls short in ovarian cancer

November 20, 2018
Manufacturing and Production, Research and Development Bavencio, Cancer, Merck MGaA, Pfizer, ovarian cancer, pharma

Merck KGaA and Pfizer’s Bavencio (avelumab) has missed its primary endpoints in the treatment of platinum-resistant or -refractory ovarian cancer, …

News
roche_dark_0

Roche withdraws Tecentriq combo application in first-line renal cell carcinoma

November 19, 2018
Sales and Marketing Cancer, Roche, avastin, pharma, renal cell carcinoma, tecentriq

The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with …

News
astrazeneca_sign_sky

AstraZeneca’s Imfinzi immunotherapy combo fails to show benefit in lung cancer

November 16, 2018
Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a …

News
boehringer_biberach_germany_copy

Boehringer signs $300 million deal with Epizyme over epigenetic cancer treatment

November 16, 2018
Medical Communications Boehringer, Cancer, Epizyme, deal, oncology

German firm Boehringer Ingelheim and the Massachusetts-based biotech Epizyme have announced that they will collaborate on the development of novel, …

News

Kymriah to be made available in UK for paediatric leukaemia patients via Cancer Drugs Fund

November 15, 2018
Sales and Marketing CAR-T, Cancer, Cancer Drugs Fund, Kymriah, NHS, NICE, leukaemia, pharma

NICE has announced its recommendation that Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) be made available in the treatment of relapsed …

News
merckentranceweb

MSD’s Keytruda improvess overall survival in Phase 3 oesophageal cancer

November 15, 2018
Research and Development Cancer, MSD, PD-L1, keytruda, pharma

MSD has announced new Phase 3 data on its anti-PD-1 therapy Keytruda (pembrolizumab) as a second-line treatment for advanced or …

News
acute_lymphoblastic_leukaemia_smear

Azacitidine and nivolumab combo proves successful in phase II trial

November 13, 2018
Manufacturing and Production Cancer, leukaemia, opdivo, pharma, texas

A combination of chemotherapy drug azacitidine and nivolumab (Bristol-Myers Squibb’s Opdivo) has proven effective in treating patients with relapsed or …

News
msd

MSD’s Keytruda chalks up FDA approval in liver cancer

November 12, 2018
Sales and Marketing Cancer, FDA, US, hepatocellular carcinoma, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda has secured another FDA approval, this time for the treatment of hepatocellular carcinoma (HCC) in patients …

News

Working Life: Philippe Bastide, Head of Biosimilars, Mundipharma

November 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Mundipharma, Philippe Bastide, biosimilars, leukaemia

“Don’t conform to what people want – take risks. The people who make a big difference are the ones who …

Feature
eisa0001

Eisai’s Lenvima wins over NICE in liver cancer in just three months

November 9, 2018
Medical Communications, Sales and Marketing Cancer, Eisai, Lenvima, Levantinib, NHS, NICE, UK, liver cancer, pharma

Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now …

News
jazz_pharma

Jazz Pharma’s Vyxeos secures NICE recommendation in acute myeloid leukaemia

November 8, 2018
Sales and Marketing Cancer, NHS, NICE, UK, Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, pharma

Jazz Pharmaceuticals has revealed that NICE has chosen to recommend that its 44mg/100mg powder formulation of Vyxeos for concentrate for …

News
787px-prostate_normal_1

Prostate cancer researchers win $2m to explore carboplatin therapy

November 7, 2018
Research and Development Cancer, carboplatin therapy, prostate cancer

The US Department of Defence has awarded a coalition of researchers – made up of the Prostate Cancer Clinical Research …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026